A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
…, JE Cortes, P Aimone… - Blood, The Journal …, 2021 - ashpublications.org
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …
[HTML][HTML] Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
…, W Bao, MJ Carrasco-Alfonso, P Aimone… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
… Carrasco-Alfonso, Paola Aimone, Maurizio Voi, Christian Doehn, Paul Russo, Cora N.
Sternberg, and on behalf of the PROTECT investigators … Carrasco-Alfonso, Paola Aimone …
Sternberg, and on behalf of the PROTECT investigators … Carrasco-Alfonso, Paola Aimone …
[HTML][HTML] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
…, I Bendit, S Cacciatore, K Titorenko, P Aimone… - Leukemia, 2021 - nature.com
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
…, C Germa, C Quadt, L Trandafir, P Aimone… - OncoTargets and …, 2016 - Taylor & Francis
The PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including
the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (…
the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (…
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double …
…, S Turri, A Chakravartty, M Chol, P Aimone… - The Lancet …, 2017 - thelancet.com
Background Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell
carcinoma of the head and neck contributes to treatment resistance and disease progression. …
carcinoma of the head and neck contributes to treatment resistance and disease progression. …
[HTML][HTML] Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study
…, GK Dy, S Thongprasert, M Reck, P Aimone… - Journal of Thoracic …, 2015 - Elsevier
Introduction The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and
treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-…
treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-…
A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours
…, MH Kulke, M Shah, D Dey, S Turri, P Aimone… - Anticancer …, 2016 - ar.iiarjournals.org
Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant …
target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant …
[HTML][HTML] Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
…, B Martino, S Saussele, FJ Giles, DM Ross, P Aimone… - Leukemia, 2021 - nature.com
The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients
with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib …
with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib …
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
…, DF McDermott, MH Voss, RE Hawkins, P Aimone… - 2017 - ascopubs.org
4506 Background: PAZ is indicated for the treatment of aRCC. The combination of an anti-angiogenic
agent and immunotherapy may improve anti-tumor activity. We report preliminary …
agent and immunotherapy may improve anti-tumor activity. We report preliminary …
Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 …
…, R McDermott, A Michael, M Izquierdo, P Aimone… - European urology, 2021 - Elsevier
… , Reaume, Stenzl, Chowdhury, McDermott, Michael, Izquierdo, Aimone, Zhang, Sternberg. …
Miguel Izquierdo and Paola Aimone are employees of and have stock options in Novartis. …
Miguel Izquierdo and Paola Aimone are employees of and have stock options in Novartis. …